HCPCS J0121: Omadacycline Injection, 1 mg
HCPCS Level II code J0121 denotes the parenteral formulation of omadacycline, billed per 1 mg unit. As an on‑label injectable antimicrobial option, this code matters nationally for hospital outpatient departments, infusion centers, and clinic-based administrations where specialty antibiotics are delivered. Accurate reporting of unit-based HCPCS drugs affects payer adjudication, inventory tracking, and national expenditure accounting for newer antimicrobial agents. Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise orientation to the clinical use and billing context for J0121, including expected service settings and the unit-based nature of reimbursement. The publication outlines typical payer coverage considerations, common modifiers used with drug administration claims (listed separately), and the kinds of benchmarks and policy updates that influence payment and utilization oversight. Clinical context addresses the role of omadacycline as an injectable antibiotic option, while billing context highlights unit reporting and site-of-service implications. Data not available in the input is clearly noted where applicable.
Sign up for hcpcs J0121 policy alerts
Get alerted when payer policies referencing J0121 are released or updated.
Billing Code Overview
HCPCS Level II code J0121 represents injection, omadacycline, 1 mg. This code is used to report administration of the antibiotic omadacycline in parenteral form. The service type is drug administration / injectable antimicrobial therapy, and the typical site of service is outpatient infusion or clinic-based injection services.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting with a confirmed or suspected bacterial infection for which intravenous or injectable omadacycline is clinically indicated. The patient may arrive to an outpatient infusion center, hospital inpatient ward, emergency department observation unit, or skilled nursing facility for administration. Prior to administration, a clinician documents indication, allergy history, weight, renal and hepatic status, and confirms culture and sensitivity results when available. Pharmacy prepares the J0121 units based on the ordered dose in milligrams, and nursing obtains venous access (peripheral IV or existing central line), verifies patient identity, reviews infusion instructions (rate, dilution), and monitors for infusion-related reactions. Typical workflow steps: medication order entry with exact mg dose converted to J0121 units, pharmacy compounding, bedside nursing verification and administration, post-infusion monitoring for adverse events, and documentation of lot number and expiration for billing compliance. Usual sites of service include outpatient infusion centers, hospital inpatient units, emergency departments, and long-term care facilities. The patient scenario commonly includes diagnoses such as community-acquired bacterial pneumonia, skin and soft tissue infection (including acute bacterial skin and skin structure infection), or other susceptible infections where omadacycline is indicated and IV or injectable therapy is used.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier or default | Rarely appended; use payer-specific guidance when no other modifier applies |
11 | Professional component | Not typically applicable to drug administration; used when reporting professional component services if separable |
22 | Increased procedural services | Use when administration required substantially greater effort or complexity beyond typical infusion |
52 | Reduced services | Use when a portion of an ordered administration was not completed |
53 | Discontinued procedure | Use when infusion is started but stopped due to patient emergency or adverse reaction |
62 | Two surgeons | Not commonly used for drug administration; included when two practitioners share responsibility for a procedure |
78 | Unplanned return to the operating/procedure room | Rare for drug infusion; use if patient returns for an invasive procedure related to infusion complication |
80 | Assistant surgeon | Not typical for medication administration; used when an assistant is required for a related procedure |
JW | Drug waste | Use to report discarded drug amount when single-dose vial contains excess and payer requires separate reporting |
JZ | No drug waste | Use when no portion of the drug is discarded from a single-dose vial |
QK | Service furnished under certain shared staffing arrangements | Use when services are provided under qualified staffing/shared responsibility per payer rules |
QX | Certified nurse-midwife or PA service | Use when a physician assistant provides the infusion service under appropriate supervision codes |
QY | Service furnished by a resident under physician billing | Use when a teaching physician bills for a service furnished by a resident in a teaching setting |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist billing under their own NPI | Use when advanced practice provider bills independently for the administration service |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Internal Medicine | Hospitalists and internists commonly order and oversee IV antibiotic therapy |
207Q00000X | Family Medicine | Primary care physicians may initiate outpatient IV antibiotic therapy or oversee infusion in office/clinic |
363L00000X | Infectious Disease | Specialists who select antimicrobial therapy and review culture/sensitivity guiding omadacycline use |
174400000X | Emergency Medicine | Emergency physicians often initiate IV antibiotic therapy for acute infections before disposition |
334800000X | Clinical Pharmacist | Pharmacists involved in dosing, compounding, and stewardship for parenteral antimicrobials |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
J13 | Pneumonia due to Streptococcus pneumoniae | Community-acquired bacterial pneumonia is a labeled indication for omadacycline in adults |
J18.9 | Pneumonia, unspecified organism | Empiric therapy for community-acquired pneumonia may use omadacycline pending organism identification |
L03.90 | Cellulitis, unspecified | Acute bacterial skin and skin structure infections (ABSSSI) such as cellulitis are treated with omadacycline in some cases |
L02.91 | Cutaneous abscess, unspecified | Purulent skin infections may be managed with appropriate systemic antibiotics including omadacycline |
A41.9 | Sepsis, unspecified organism | Systemic infection secondary to bacterial sources may prompt IV antibiotic therapy including omadacycline when appropriate |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | Often billed for the initial infusion administration time when omadacycline is given intravenously |
96366 | Intravenous infusion, each additional hour (list separately in addition to code for primary service) | Billed when the infusion duration extends beyond the first hour for prolonged infusions |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Used if omadacycline is administered intramuscularly rather than IV when clinically appropriate |
36415 | Collection of venous blood by venipuncture | Performed before or during therapy for culture, drug level, or baseline labs related to antibiotic therapy |
99024 | Postoperative follow-up visit, related to procedure during global period | Used rarely for follow-up assessment related to adverse events from infusion in settings where applicable |